VARSETATUG
UNII NPE2WM3V8G

Substance Identification & Data

This profile provides standardized clinical and technical data for Varsetatug, uniquely identified by the FDA Unique Ingredient Identifier (UNII) NPE2WM3V8G.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3036004-28-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

NPE2WM3V8G

CAS Registry Number

3036004-28-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

VARSETATUG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C223315

National Cancer Institute reference terminology for clinical and research data.

INN ID

13676

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Varsetatug. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

VARSETATUG

Common Names & Synonyms

H-GAMMA1 HEAVY CHAIN HUMANIZED (1-445) (VH (HOMO SAPIENS IGHV1-3*01 (81.6%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (111), CDR-IMGT (8.8.9) (26-33.51-58.97-105)) (1-116) -HOMO SAPIENS IGHG1*01 (100%) G1M17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (213) (117-214), HINGE 1-15 (215-229), CH2 (230-339), CH3 D12 (355), L14 (357) (340-444), CHS K2>DEL (445)) (117-445)), (219-265')-DISULFIDE WITH L-KAPPA LIGHT CHAIN HUMANIZED FUSED AT ITS N-TERMINAL END TO A CLEAVABLE PRODOMAIN (1'-265') (PRODOMAIN (1'-46') -HOMO SAPIENS V-KAPPA (HOMO SAPIENS IGKV2D-29*02 (86.0%) -IGKJ2*01 (100%), CDR-IMGT (11.3.9) (73'-83'.101'-103'.140'-148')) (47'-158') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (C-KAPPA A45.1 (204'), V101 (242')) (159'-265')); DIMER (225-225'':228-228'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-DG44, GLYCOFORM ALFA

IMMUNOGLOBULIN G1 (DE-446-LYSINE), ANTI-(HUMAN EPITHELIAL CELL ADHESION MOLECULE) (HUMAN MONOCLONAL CX-231 .GAMMA.1-CHAIN), DISULFIDE WITH PRODOMAIN PEPTIDE (SYNTHETIC MASKING MOIETY AND PROTEASE-CLEAVABLE MOIETY) FUSION PROTEIN WITH HUMAN MONOCLONAL CX-231 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS EPCAM (EPITHELIAL CELL ADHESION MOLECULE, TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 1, TACSTD1, GASTROINTESTINAL TUMOR-ASSOCIATED PROTEIN 2, GA733-2, EPITHELIAL GLYCOPROTEIN 2, EGP-2, KSA, KS1/4 ANTIGEN, M4S1, TUMOR ANTIGEN 17-1A, EP-CAM, EPCAM, CD326)), HUMANIZED MONOCLONAL ANTIBODY WITH A CLEAVABLE PRODOMAIN OF 46 AMINO ACIDS FUSED AT THE N-TERMINAL END OF THE L-KAPPA LIGHT CHAINS (VARSETATUG)

VARSETATUG [INN]

External Clinical & Regulatory Resources

Previous UNIINPD9S131ZU

Next UNIINPE78BL95F